Teleflex Incorporated research snapshot
TFX AI stock analysis as of the August 3, 2026 data cutoff reads Teleflex as a focused transformation story: it is selling the acute care, interventional urology, and OEM businesses, plans a $1 billion buyback and $800 million of debt paydown with the roughly $1.8 billion net proceeds, and expects a significant adjusted EPS step-up in 2027 once the divestitures close and stranded costs are offset. The stock traded at $142.86 to $143.47 on the morning of August 3, up about 4.5% to 4.9% from the $136.71 July 31 close after a fresh 52-week high of $143.47, helped by the July 29 FDA BLA approval of EZPLAZ freeze-dried plasma and a July 31 Needham price target raise to $159. Q1 2026 revenue rose 32.3% on a GAAP basis and 5.1% on a pro forma adjusted constant currency basis, while adjusted EPS fell 3.5% to $1.39 on tariffs, the third-party supplier recall, and acquisition-related costs. The FY2026 adjusted EPS guidance of $6.25 to $6.55 is a transition-year number that excludes the buyback and debt benefits, while the Street consensus points to about $10.58 for FY2027. At the cutoff, the stock carried a market capitalization near $6.32 to $6.35 billion, a forward P/E near 18 to 21 times depending on the estimate basis, negative trailing GAAP earnings, and net leverage near 2.5 times. This TFX AI stock analysis is informational research using scenario ranges, not investment advice.
Current price
$142.86 to $143.47 during the August 3, 2026 morning session, up about 4.5% to 4.9% from the $136.71 July 31 close, after opening at $138.25
Market cap
$6.35 billion per StockAnalysis, with $6.32 billion computed as $142.86 times 44.27 million shares
AI score
61 / 100
Rating
Focused transformation with a 2027 EPS step-up ahead of the August 6 report
Trend status
Bullish above the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages after printing a new 52-week high of $143.47 on August 3
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Teleflex is a focused medical technology company selling single-use devices for vascular access, interventional procedures, and surgery. Q1 2026 pro forma adjusted constant currency growth was 5.1%, aligned with the 4.5% to 5.5% FY2026 guidance, and the go-forward portfolio is centered on higher-growth critical care and cath lab markets. | Medium |
| Moat | Modest moat from physician training, regulatory clearances, and brands such as Arrow, EZ-IO, Weck, and MANTA, plus the new EZPLAZ freeze-dried plasma franchise with FDA BLA approval. Switching costs vary by product line and several categories face competition from larger medtech players. | Medium-low |
| Management | New CEO Jason Weidman started June 8, 2026 after a Medtronic career, replacing interim CEO Stuart Randle. The board is executing a portfolio transformation with divestitures, a $1 billion buyback, $800 million debt paydown, and a $50 million restructuring, but the FY2025 goodwill impairment and an FTC second request keep execution risk real. | Medium |
| Financial trend | FY2025 continuing operations delivered adjusted EPS of $6.98, up 8.7%, and Q1 2026 adjusted EPS fell 3.5% to $1.39 on tariffs, the third-party supplier recall, and acquisition costs. FY2026 adjusted EPS guidance is $6.25 to $6.55, a transition year that excludes buyback and debt benefits, with consensus modeling about $10.58 for FY2027. | Medium |
| Valuation | At $142.86, TFX trades near 18.4 times forward earnings on the StockAnalysis statistics basis, about 2.9 times sales, 2.0 times book value, and 26.7 times trailing free cash flow. The multiples are hard to anchor because GAAP earnings are negative and the forward number is a transition-year EPS that excludes buyback benefits. | Low-medium |
| Technical trend | TFX traded at $142.86 to $143.47 on August 3, above the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages of about $135.98, $133.99, $131.20, $126.62, and $121.23, with a fresh 52-week high of $143.47 and 14-day RSI near 64, strong but not overbought. | Medium |
| Risk level | Risk is elevated. Net leverage is near 2.5 times, the divestitures face an FTC second request on the acute care and interventional urology sale, a third-party supplier recall is being remediated, tariffs are a $33 million FY2026 assumption, and the 2027 step-up depends on closing and buyback execution. | Medium |
| AI confidence | High for descriptive facts, quote data, and cross-checked math that matched across StockAnalysis.com and SEC EDGAR XBRL. Lower for forward return estimates because divestiture timing, buyback pace, tariffs, and the recall make the 2027 earnings bridge uncertain. | Medium data confidence |
| Investment certainty | Medium-low. The page gives a research framework and scenario ranges, not a buy or sell instruction, and the transformation upside is balanced against transition-year earnings and leverage. | Medium-low |
TFX AI stock forecast
The TFX AI stock forecast uses scenario math around the $142.86 August 3, 2026 reference and the FY2026 adjusted EPS consensus of $6.67. The three-scenario framework produced a bearish area near $95, a base area near $147, and a bullish area near $203 over three years, using adjusted EPS growth of 3%, 9%, and 15% and exit multiples of 13 times, 17 times, and 20 times. The base area sits close to the $147.45 average analyst target. The scenarios do not assume the FY2027 consensus of about $10.58, which reflects the divestiture proceeds, buyback, and debt paydown and would lift all three outcomes if delivered. These are scenarios, not price commitments.
$195 to $215
More likely if the acute care, interventional urology, and OEM divestitures close on schedule, the $1 billion buyback and $800 million debt paydown push FY2027 adjusted EPS toward the roughly $10.58 consensus, EZPLAZ freeze-dried plasma and Freesolve adoption accelerate, and the market holds a high-teens exit multiple.
$135 to $160
More likely if pro forma adjusted constant currency growth stays near 5%, FY2026 adjusted EPS lands in the $6.25 to $6.55 guidance range, the divestitures close by the end of 2026, and TFX holds a low-to-mid-teens forward multiple near the average analyst target.
$80 to $105
More likely if the FTC second request delays the acute care sale, the supplier recall or the interventional sales force integration disrupts growth, tariffs or stranded costs exceed guidance, FY2027 adjusted EPS falls short of consensus, or leverage stays near 2.5 times longer than planned.
TFX AI technical analysis
TFX AI technical analysis is bullish as of the August 3, 2026 cutoff. The stock traded at $142.86 to $143.47, up about 4.5% to 4.9% from the $136.71 July 31 close, and printed a new 52-week high of $143.47, above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Barchart reported the 5-day average near $135.98, the 20-day near $133.99, the 50-day near $131.20, the 100-day near $126.62, and the 200-day near $121.23, with 14-day RSI near 64 and 14-day ADX near 10, meaning the move is strong but the trend measure is still low and the stock could be extended after the run-up.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $142.86 to $143.47 | StockAnalysis real-time quote during the August 3, 2026 morning session, up about 4.5% to 4.9% from the $136.71 July 31 close, after opening at $138.25. |
| 52-week range | $100.18 to $143.47 | TFX printed a fresh 52-week high of $143.47 on August 3, 2026, with the $100.18 low from the trailing 52 weeks as the major downside reference. |
| Near support | $134 to $136 | The 5-day and 20-day moving averages near $135.98 and $133.99 form the first pullback support zone on Barchart. |
| Next support | $131 to $133 | The 50-day moving average near $131.20 on Barchart, matching about $131.19 on StockAnalysis, is the second support level. |
| Key support | $121 to $126 | The 200-day moving average near $121.23 and the 100-day near $126.62 form the major support cluster for the medium-term trend. |
| Resistance | $143.50 to $145 | The August 3 high near $143.47 is the immediate ceiling, with the $145 area as psychological resistance ahead of the August 6 earnings report. |
| Momentum | RSI near 64 | 14-day RSI was near 64.38 on Barchart and 63.75 on StockAnalysis, strong but not overbought, after the post-approval run-up. |
| Volume | About 410,000 average shares | Barchart listed 20-day average volume near 410,794 shares and StockAnalysis near 411,524 on August 3, 2026, useful for checking the breakout quality near the high. |
| Volatility | Elevated into earnings | Barchart reported 14-day historical volatility near 28.69% and 9-day near 33.16%, and the August 6 earnings report is a scheduled volatility event. |
| Invalidation | Close below $134 | A decisive close below the 5-day and 20-day averages near $135.98 and $133.99 would weaken the short-term setup; a move below the 50-day near $131 would put the medium-term trend at risk. |
TFX AI trading strategy
The TFX AI trading strategy below is a rules-based research framework, not personal advice. It connects the transformation plan, the 2027 EPS step-up, the balance sheet, and technical confirmation with defined invalidation levels.
Watch for TFX to hold above the $134 to $136 support zone and to confirm the new 52-week high near $143.47 on volume above the 410,000 share average. Confirmation should include an August 6 earnings report that keeps FY2026 adjusted EPS guidance near $6.25 to $6.55 and progress on the divestiture and buyback timeline.
A daily close below the 5-day and 20-day moving averages near $135.98 and $133.99 should reduce setup confidence, since the stock is extended after the run-up and earnings add binary risk.
If TFX pulls back toward the $131 to $133 zone after earnings without a guidance cut, compare the selloff with the divestiture timeline, the buyback start, tariff assumptions, and the supplier recall remediation before acting.
Do not treat weakness as a buying opportunity if it is tied to a delay in the FTC review, a missed FY2026 EPS guidance range, or worsening recall or integration disruption.
Track the closing of the acute care, interventional urology, and OEM divestitures, the net after-tax proceeds near $1.8 billion, the $1 billion buyback execution, the $800 million debt paydown, net leverage, stranded cost mitigation, and FY2027 adjusted EPS progression toward the roughly $10.58 consensus.
Position sizing should reflect the transition-year earnings, the ~2.5 times net leverage, the ~0.97% dividend yield, and the fact that the 2027 step-up is conditional on execution rather than guaranteed.
Investment research summary
Teleflex is paid because hospitals and cath labs need reliable single-use devices for vascular access, interventional procedures, and surgery. The value is procedural efficiency, patient safety, and clinical reliability, and the go-forward portfolio is being narrowed to critical care and high-acuity hospital markets.
Teleflex has moderate competitive advantages in niche categories such as intraosseous access (EZ-IO), vascular closure (MANTA), surgical ligation (Weck), and now freeze-dried plasma (EZPLAZ). Switching costs and brand strength vary by product line, and several categories face competition from larger medtech players.
The thesis fails if the acute care and interventional urology divestiture is delayed by the FTC second request, if the supplier recall or sales force integration disrupts growth, if tariffs exceed the $33 million assumption, if stranded costs are not offset by transition services, or if FY2027 adjusted EPS falls well short of the roughly $10.58 consensus.
CEO Jason Weidman, who started June 8, 2026 after a Medtronic career, is taking over an executing transformation plan. The board has already signed the divestitures, announced a $1 billion buyback, an $800 million debt paydown, and a $50 million restructuring, but the FY2025 goodwill impairment and the FTC second request mean the capital allocation and portfolio record is still being written.
Aging populations, rising chronic disease prevalence, adoption of minimally invasive procedures, and growth in interventional cardiology support long-term demand for Teleflex products, while hospital cost containment, group purchasing organization pricing pressure, tariffs, and medtech consolidation create headwinds.
At $142.86 with a transition-year forward P/E near 18 to 21 times, TFX is not a distressed value. The margin of safety depends on whether the 2027 adjusted EPS step-up toward the roughly $10.58 consensus is delivered, whether net leverage comes down with the $800 million debt paydown, and whether the buyback is executed within the $1 billion authorization.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $142.86 to $143.47 during the August 3, 2026 morning session, up about 4.5% to 4.9% from the $136.71 July 31 close, after opening at $138.25, with a fresh 52-week high of $143.47 | StockAnalysis.com TFX real-time quote | August 3, 2026 |
| Market capitalization | $6.35 billion per StockAnalysis, with $6.32 billion computed as $142.86 times 44.27 million shares, a 0.40% deviation that cross-validates the share count | StockAnalysis.com statistics and Pineify financial_rigor.py | August 3, 2026 |
| Shares outstanding | 44.27 million shares outstanding, down 5.32% year over year, with a float of 44.11 million and institutional ownership above 100% | StockAnalysis.com statistics | August 3, 2026 |
| TTM revenue | $2.13 billion over the trailing twelve months ended March 31, 2026, matching the sum of the reported continuing operations quarters | StockAnalysis.com statistics and SEC EDGAR XBRL | August 3, 2026 |
| Q1 2026 revenue | $548.3 million, up 32.3% on a GAAP basis and 5.1% on a pro forma adjusted constant currency basis | Teleflex Q1 2026 earnings release and earnings call | May 7, 2026 |
| Q1 2026 adjusted EPS | $1.39, down 3.5% year over year, with adjusted gross margin of 61.4% and adjusted operating margin of 18.1% | Teleflex Q1 2026 earnings call | May 7, 2026 |
| Q1 2026 segment growth | Vascular revenue up 4.8% to $236.8 million, Interventional up 3.0% to $204.7 million, and Surgical up 9.9% to $106.8 million | Teleflex Q1 2026 earnings call | May 7, 2026 |
| FY2025 adjusted results | Adjusted EPS of $6.98, up 8.7%, with adjusted gross margin of 63.7% and adjusted operating margin of 22.7% for continuing operations | Teleflex Q4 2025 earnings call | February 26, 2026 |
| FY2025 GAAP net income | Net loss of $905.64 million for fiscal 2025, reflecting roughly $400 million of goodwill impairment and related charges, with GAAP diluted EPS of about negative $20.25 | SEC EDGAR XBRL and StockAnalysis.com financials | August 3, 2026 |
| FY2026 adjusted EPS guidance | $6.25 to $6.55, excluding the buyback and debt paydown benefits | Teleflex Q1 2026 earnings call | May 7, 2026 |
| FY2026 revenue guidance | Pro forma adjusted constant currency growth of 4.5% to 5.5%, with adjusted operating margin near 19%, reflecting roughly $90 million of stranded costs | Teleflex Q1 2026 earnings call | May 7, 2026 |
| FY2027 consensus | Consensus adjusted EPS near $10.58 for FY2027, up about 58.7%, reflecting divestiture proceeds, the $1 billion buyback, and the $800 million debt paydown | StockAnalysis.com forecast | July 31, 2026 |
| Strategic divestitures | Agreements to sell the acute care, interventional urology, and OEM businesses for total cash proceeds of $2.03 billion and net after-tax proceeds of about $1.8 billion, with closings expected in the second half of 2026 and an FTC second request on the acute care and interventional urology sale | Teleflex Q1 2026 earnings call | May 7, 2026 |
| Capital allocation plan | $1 billion share repurchase authorization, $800 million debt reduction, opportunistic buybacks expected to begin in the second quarter of 2026, and net leverage near 2.5 times at the end of Q1 2026 | Teleflex Q1 2026 earnings call | May 7, 2026 |
| Cash and debt | Cash and equivalents of $309.4 million as of March 31, 2026, with long-term debt of about $2.51 billion and short-term debt of about $103 million, and StockAnalysis reporting cash of $333.06 million and total debt of $2.74 billion under its classification | SEC EDGAR XBRL and StockAnalysis.com statistics | August 3, 2026 |
| Free cash flow | Operating cash flow of $316.61 million and free cash flow of $226.71 million over the trailing twelve months, with capital expenditures of $89.90 million | StockAnalysis.com statistics | August 3, 2026 |
| Valuation check | Forward P/E near 18.39 on the StockAnalysis statistics basis, PS near 2.85, PB near 1.96, P/FCF near 26.70, EV/EBITDA near 45.88, and EV/Sales near 3.98 | StockAnalysis.com statistics | August 3, 2026 |
| Dividend | Annual dividend of $1.36 per share with a 0.97% yield, paid quarterly at $0.34 per share, with the last ex-dividend date on May 22, 2026 | StockAnalysis.com dividend history | August 3, 2026 |
| Analyst consensus and target | Hold consensus with an average target of $147.45 across 13 analysts, low $135 and high $160, with Needham raising its target to $159 from $147 on July 31, 2026 and UBS initiating at Neutral with a $145 target on July 28, 2026 | StockAnalysis.com forecast and analyst ratings | July 31, 2026 |
| Short interest | 2.78 million shares short, or 6.29% of shares outstanding, with a 6.21 day short ratio, up from 2.31 million shares the prior month | StockAnalysis.com statistics | August 3, 2026 |
| Technical snapshot | 5-day moving average near $135.98, 20-day near $133.99, 50-day near $131.20, 100-day near $126.62, 200-day near $121.23, 14-day RSI near 64.38, 14-day ADX near 10.24, and 14-day historical volatility near 28.69% | Barchart and StockAnalysis.com technical snapshots | August 3, 2026 |
| EZPLAZ freeze-dried plasma approval | On July 29, 2026, the FDA granted BLA approval for EZPLAZ freeze-dried plasma, the first freeze-dried plasma product licensed for use in the United States | Teleflex press release via StockAnalysis.com news feed | July 29, 2026 |
| Three-scenario fair value (3-year) | Bullish $203, Base $147, Bearish $95 per Pineify financial_rigor.py, using the FY2026 adjusted EPS consensus of $6.67 with adjusted EPS growth of 15%, 9%, and 3% and exit multiples of 20 times, 17 times, and 13 times | Pineify financial_rigor.py three-scenario model and StockAnalysis.com consensus estimates | August 3, 2026 |
This TFX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of the August 3, 2026 data cutoff and may be wrong if the divestiture timeline, the FTC review, buyback execution, tariffs, recall remediation, competitive dynamics, market multiples, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
